Skip to main content
SpringerLink
Log in

Anidulafungin

A Viewpoint by José A. Vazquez

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770–5

    Article  PubMed  CAS  Google Scholar 

  2. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrobial Agents Chemother 2004 Jun; 48(6): 2021–4

    Article  CAS  Google Scholar 

  3. Vazquez J, Schranz J, Krause D, et al. Efficacy results from a phase 2/3 study of anidulafungin in patients with azole-refractory mucosal candidiasis [abstract no. M-1038]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC. In Press

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA

    José A. Vazquez

Authors
  1. José A. Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vazquez, J.A. Anidulafungin. Drugs 64, 2259–2260 (2004). https://doi.org/10.2165/00003495-200464190-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464190-00013

Search

Navigation